Table 2

Number of asthma-associated complications and healthcare service engagements reported from 12 months before commencing IL-5 inhibitor treatment to 18 months of IL-5 inhibitor treatment

Mean% nil exacerbationP valueORCI
Exacerbation—hospitalisation
Baseline (n=230)1.4252%
(n=121)
6 months (n=191)0.2184%
(n=160)
Baseline–6 months
p<0.001
0.150.10 to 0.20
12 months (n=135)0.2882%
(n=110)
Baseline–12 months
p<0.001
0.210.15 to 0.30
18 months (n=97)0.3480%
(n=78)
Baseline–18 months p<0.0010.270.18 to 0.38
Exacerbation—community treated
Baseline (n=230)1.0965% (n=149)
6 months (n=191)0.1689%
(n=169)
Baseline–6 months
p<0.001
0.140.10 to 0.21
12 months (n=135)0.2485%
(n=115)
Baseline–12 months
p<0.001
0.210.14 to 0.30
18 months (n=97)0.2486%
(n=83)
Baseline–18 months p<0.0010.220.14 to 0.35
Oral corticosteroid use
Baseline (n=153)6.81 mg6% (n=9)
6 months (n=153)0.24 mg81%
(n=125)
Baseline–6 months
p<0.001
0.110.09 to 0.14
12 months (n=135)0.36 mg78%
(n=105)
Baseline–12 months
p<0.001
0.220.18 to 0.26
18 months (n=97)0.40 mg77%
(n=75)
Baseline–18 months p<0.0010.280.23 to 0.34
GP visitsSix or less visits
Baseline (n=230)6.6858%
(n=133)
6 months (n=191)0.8399%
(n=190)
Baseline–6 months
p<0.001
0.030.025 to 0.045
12 months (n=135)1.1696%
(n=129)
Baseline–12 months
p<0.001
0.050.04 to 0.07
18 months (n=97)2.1694% (n=8)Baseline–18 months p<0.0010.060.04 to 0.08
  • Baseline = number of reported events in the 12 months prior to starting IL-5 treatment.

  • Exacerbation = increase in asthma symptoms requiring oral corticosteroid treatment/increase in maintenance oral corticosteroid dose for management.

  • Exacerbation—hospitalisation = number of recorded exacerbations requiring inpatient hospital treatment of at least 1 day.

  • Exacerbation—non-inpatient = recorded exacerbations requiring specialist respiratory review but not requiring inpatient management.

  • Oral corticosteroid = average number of courses of oral corticosteroid/increase in maintenance oral corticosteroid dose prescribed for treatment of asthma symptoms.

  • GP visit = recorded visits to General Practitioner for respiratory-associate symptoms.

  • Mean = average number of events per patient over the started time period.

  • % nil exacerbation = the percentage of patients in each analysis who reported no exacerbations over the stated time period.

  • n = total number of patients included in each analysis.

  • P value = significance measure of change in results over the stated time period.

  • 6 months = total number of events recorded in the 6 months following commencement of IL-5 inhibitor treatment. 12 months = total number of events recorded in the 12 months following commencement of IL-5 inhibitor treatment. 18 months = total number of events recorded in the 18 months following commencement of IL-5 inhibitor treatment.